Home >> Signaling Pathways >> Others >> Inhibitory Antibodies

Inhibitory Antibodies

Products for  Inhibitory Antibodies

  1. Cat.No. Product Name Information
  2. GC66199 Alemtuzumab Alemtuzumab (Campath-IH) is a humanized monoclonal antibody against CD52, a glycoprotein expressed on the surface of most lymphoid, and to a lesser extent, myeloid cell types. Alemtuzumab selectively targets the CD52 antigen to induce profound lymphocyte depletion, followed by recovery of T and B cells with regulatory phenotypes. Alemtuzumab  Chemical Structure
  3. GC68370 Amatuximab Amatuximab  Chemical Structure
  4. GC68343 Anifrolumab Anifrolumab  Chemical Structure
  5. GC66388 Anti-Mouse CTLA-4 Antibody Anti-Mouse CTLA-4 Antibody is an anti-mouse CTLA-4 IgG2b antibody inhibitor derived from host mouse. Anti-Mouse CTLA-4 Antibody  Chemical Structure
  6. GC66336 Anti-Mouse NK1.1 Antibody Anti-Mouse NK1.1 Antibody is an anti-mouse NK1.1 IgG2a antibody inhibitor derived from host mouse. Anti-Mouse NK1.1 Antibody  Chemical Structure
  7. GC68347 ATG-031 ATG-031  Chemical Structure
  8. GC66359 Atibuclimab Atibuclimab, is a chimeric monoclonal antibody directed against CD14 and is composed of murine variable and human IgG4 Fc regions. Atibuclimab can be used for the research of amyotrophic lateral sclerosis. Atibuclimab attenuates LPS-induced symptoms and strongly inhibits LPS-induced proinflammatory cytokine release, while only delaying the release of the anti-inflammatory cytokines soluble TNF receptor type I and IL-1 receptor antagonist. Atibuclimab  Chemical Structure
  9. GC65061 Blinatumomab

    Blinatumomab (Anatumomab) is a bispecific monoclonal antibody which can specifically targets the CD19 antigen present on B cells. Blinatumomab can be used for the research of acute lymphoblastic leukemia.

    Blinatumomab  Chemical Structure
  10. GC66384 Blosozumab Blosozumab (LY2541546) is an anti-Human sclerostin (SOST) antibody inhibitor. Blosozumab stimulates bone formation and reduces bone resorption. Blosozumab can be used in the research of Osteoporosis. Blosozumab  Chemical Structure
  11. GC67763 Burosumab Burosumab  Chemical Structure
  12. GC68345 Caplacizumab Caplacizumab  Chemical Structure
  13. GC66380 Emactuzumab Emactuzumab(RG 7155) is a specific monoclonal antibody that inhibits colonystimulating factor 1 receptor (CSF1R) activation. Emactuzumab has high affinity for CSF-1R with Ki value of 0.2 nM to blocks CSF-1R dimerization. Emactuzumab can be used for the research of several diseases, such as diffuse-type tenosynovial giant cell tumour (dt-GCT) . Emactuzumab  Chemical Structure
  14. GC68334 Enoblituzumab Enoblituzumab  Chemical Structure
  15. GC64479 Gemtuzumab ozogamicin Gemtuzumab ozogamicin is an antibody-drug conjugate (ADC) consisting of a monoclonal antibody targeting CD33 linked to a cytotoxic derivative of Calicheamicin. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia. Gemtuzumab ozogamicin  Chemical Structure
  16. GC63009 Human IgG1 kappa, Isotype Control Human IgG1 kappa, Isotype Control, a human monoclonal antibody, is an isotype control for human IgG1κ antibody. Human IgG1 kappa, Isotype Control  Chemical Structure
  17. GC65240 Human IgG4 kappa, Isotype Control Human IgG4 kappa, Isotype Control, a human monoclonal antibody, is an isotype control for human IgG4κ antibody. Human IgG4 kappa, Isotype Control  Chemical Structure
  18. GC68367 Ieramilimab Ieramilimab  Chemical Structure
  19. GC69355 Landogrozumab

    Landogrozumab (LY2495655) is a humanized monoclonal antibody against myostatin, which effectively improves muscle volume, grip strength and function. Landogrozumab can be used in research related to muscle atrophy diseases.

    Landogrozumab  Chemical Structure
  20. GC66358 Lemzoparlimab Lemzoparlimab (TJ011133; TJC4) is a humanized anti-CD47 IgG4 antibody. Lemzoparlimab has a strong anti-tumor activity. Lemzoparlimab  Chemical Structure
  21. GC68368 Magrolimab Magrolimab  Chemical Structure
  22. GC66351 Mosunetuzumab Mosunetuzumab (BTCT-4465A) is a humanized, immunoglobulin G1-based bispecific antibody targeting CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs). Mosunetuzumab  Chemical Structure
  23. GC68338 Naxitamab Naxitamab  Chemical Structure
  24. GC68357 Nesvacumab Nesvacumab  Chemical Structure
  25. GC68301 Nipocalimab Nipocalimab  Chemical Structure
  26. GC69604 Ociperlimab

    Ociperlimab is a humanized IgG1 antibody against TIGIT. Ociperlimab binds with high affinity to the extracellular domain of human TIGIT (KD = 0.135 nM). It blocks the interaction between TIGIT and its ligands PVR or PVR-L2. Ociperlimab can be used for cancer research.

    Ociperlimab  Chemical Structure
  27. GC65498 Ofatumumab Ofatumumab (Arzerra) is a fully human anti-CD20 monoclonal antibody that induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity in CD20-expressing B lymphocytes. Ofatumumab  Chemical Structure
  28. GC66330 Omburtamab Omburtamab is an anti-CD276 (also known as B7-H3) monoclonal antibody, CD276 is a B7/CD28 immunoglobulin superfamily member expressed among solid human tumours. Omburtamab can bind tumor tissues and be used in various cancers research. Omburtamab  Chemical Structure
  29. GC69626 Ontuxizumab

    Ontuxizumab (MORAb-004) is a monoclonal antibody of the IgG1/κ class that targets tumor endothelial markers 1 (TEM-1) or CD248 and has anti-tumor effects. Ontuxizumab can be used in cancer research.

    Ontuxizumab  Chemical Structure
  30. GC69628 Opicinumab

    Opicinumab (BIIB033) is a monoclonal antibody that targets LINGO-1 and has potential applications in acute optic neuritis and relapsing multiple sclerosis.

    Opicinumab  Chemical Structure
  31. GC69632 Orilanolimab

    Orilanolimab (SYNT001) is a humanized, de-immunized monoclonal antibody that blocks FcRn. Orilanolimab inhibits the interaction between FcRn and the Fc portion of IgG molecules. Orilanolimab impairs FcRn-mediated adaptive immune function activated by IgG ICs. Orilanolimab can disrupt IgG homeostasis and innate and adaptive immunity.

    Orilanolimab  Chemical Structure
  32. GC69664 Pascolizumab

    Pascolizumab (SB-240683) is a humanized monoclonal antibody against IL-4. Pascolizumab has potential for asthma research.

    Pascolizumab  Chemical Structure
  33. GC69685 Pepinemab

    Pepinemab (VX 15/2503) is a humanized monoclonal antibody against SEMA4D, also known as CD100. SEMA4D is a signaling protein that regulates neuronal development and plays a role in various cellular processes. Pepinemab can be used for research on neurodegenerative diseases such as Alzheimer's disease by blocking the activity of SEMA4D.

    Pepinemab  Chemical Structure
  34. GC69735 Prezalumab

    Prezalumab (AMG 557) is a human IgG2 monoclonal antibody that targets ICOSL and BAFF. Prezalumab has been studied for its effects on systemic lupus erythematosus arthritis. Prezalumab can be used in research for skin lupus erythematosus, psoriasis, and systemic lupus erythematosus (SLE).

    Prezalumab  Chemical Structure
  35. GC66381 Relatlimab Relatlimab (BMS-986016) is a human monoclonal antibody anti-LAG-3 antibody generated by immunization of transgenic mice bearing human immunoglobulin miniloci with recombinant LAG-3 protein. Relatlimab blocks LAG-3/MHC II interaction with an IC50 value of 0.67 nM and LAG-3/FGL1 interaction with an IC50 value of 0.019 nM. Relatlimab can be used in research of cancer. Relatlimab  Chemical Structure
  36. GC69826 Rocatinlimab

    Rocatinlimab (AMG 451) (KHK4083) is a fully human, non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody against OX40. Rocatinlimab can be used for the study of atopic dermatitis (AD).

    Rocatinlimab  Chemical Structure
  37. GC69832 Rosmantuzumab

    Rosmantuzumab (OMP-131R10) is a humanized monoclonal antibody that targets R-spondin 3 (RSPO3). It can be used for the study of advanced, recurrent, and refractory solid tumors.

    Rosmantuzumab  Chemical Structure
  38. GC68285 Rosopatamab Rosopatamab  Chemical Structure
  39. GC64424 Sabatolimab Sabatolimab (MBG453) is a high-affinity, humanized, IgG4 (S228P) antibody targeting TIM-3, an inhibitory receptor that regulates adaptive and innate immune responses. Sabatolimab  Chemical Structure
  40. GC65538 Sacituzumab Sacituzumab is a humanized IgG1 monoclonal antibody for anti-trophoblast cell-surface antigen 2 (anti-Trop-2). Sacituzumab has?the?potential?for metastatic triple-negative breast cancer research. Sacituzumab  Chemical Structure
  41. GC69855 Samalizumab

    Samalizumab (ALXN 6000) is a humanized monoclonal antibody that specifically binds to CD200 and blocks its connection with the CD200 receptor (CD200R). Samalizumab can be used in research for multiple myeloma and B-cell chronic lymphocytic leukemia.

    Samalizumab  Chemical Structure
  42. GC65512 Selicrelumab Selicrelumab is an agonist CD40 antibody, induces changes in the tumor microenvironment. Selicrelumab can be used for the research of pancreatic cance and neoadjuvant study. Selicrelumab  Chemical Structure
  43. GC69887 Sibeprenlimab

    Sibeprenlimab (VIS649) is a humanized IgG2 monoclonal antibody. Sibeprenlimab can inhibit APRIL and may be used in the research of IgA nephropathy (IgAN).

    Sibeprenlimab  Chemical Structure
  44. GC69924 Sofituzumab

    Sofituzumab (MMUC 1206A) is a humanized anti-MUC16 recombinant V-kappa antibody.

    Sofituzumab  Chemical Structure
  45. GC69927 Sontuzumab

    Sontuzumab (AS1402) is a humanized IgG1κ monoclonal antibody that specifically targets MUC1. Sontuzumab binds to the extracellular peptide sequence PDTR of MUC1 with a Kd of approximately 1 nM. Sontuzumab can be used for research on breast cancer.

    Sontuzumab  Chemical Structure
  46. GC68356 Sotigalimab Sotigalimab  Chemical Structure
  47. GC69986 Tanezumab

    Tanezumab (RN-624) is a humanized monoclonal antibody with high affinity and specificity that can block the binding of NGF to receptors p75 and TrkA in the peripheral nervous system. Tanezumab can be used for acute and chronic pain, such as osteoarthritis, knee joint and neuropathic pain, and postherpetic neuralgia research.

    Tanezumab  Chemical Structure
  48. GC69996 Tavolixizumab

    Tavolixizumab (MEDI 0562; Tavolimab) is a humanized monoclonal antibody against TNFRSF4 (tumor necrosis factor receptor superfamily member 4), which can be used in cancer immunotherapy research.

    Tavolixizumab  Chemical Structure
  49. GC70005 Telazorlimab

    Telazorlimab (GBR-830) is a humanized monoclonal antibody targeting the OX40 co-stimulatory receptor on activated T cells. Telazorlimab can be used for research in autoimmune diseases.

    Telazorlimab  Chemical Structure
  50. GC70006 Telisotuzumab

    Telisotuzumab (ABT-700) is a humanized recombinant bivalent antibody that targets the hepatocyte growth factor receptor (MET) as a therapeutic antibody. It can bind to c-Met with high affinity and inhibit c-Met signaling. Telisotuzumab has anti-tumor activity.

    Telisotuzumab  Chemical Structure
  51. GC70008 Telitacicept

    Telitacicept (RC18) is a fully human TACI-Fc fusion protein. Telitacicept is a dual B lymphocyte stimulator (BLyS)/APRIL (a proliferation-inducing ligand) inhibitor that effectively blocks the proliferation of B lymphocytes. Telitacicept can be used in research on B cell autoimmune diseases.

    Telitacicept  Chemical Structure
  52. GC70010 Tenatumomab

    Tenatumomab (ST2146) is a mouse-derived monoclonal antibody against tenascin-C, a large extracellular glycoprotein that is overexpressed in cancer. Tenatumomab has been used in pre-targeted radioimmunotherapy studies (PAGRIT), and delivers radioactive isotopes to tumors through PAGRIT and direct 131 iodine labeling methods.

    Tenatumomab  Chemical Structure
  53. GC70018 Tesnatilimab

    Tesnatilimab is a humanized IgG4 monoclonal antibody that targets the immune activating receptor NKG2D and has potential immunomodulatory and anti-inflammatory activity. Tesnatilimab can be used in research for inflammatory bowel disease (IBD).

    Tesnatilimab  Chemical Structure
  54. GC66397 Tinurilimab Tinurilimab (Bay 1834942) is an anti-CEACAM6 monoclonal antibody. CEACAM6 is an immune checkpoint regulator suppressing the activity of effector T-cells against tumors. Tinurilimab  Chemical Structure
  55. GC68355 Tiragolumab Tiragolumab  Chemical Structure
  56. GC70057 Tregalizumab

    Tregalizumab is a humanized monoclonal antibody (IgG1 type) that selectively activates the suppressive properties of regulatory T cells (Tregs) in vitro. It can be used for research on autoimmune diseases (caused by insufficient Treg activity) and allergies.

    Tregalizumab  Chemical Structure
  57. GC70073 TSR-033

    TSR-033 is a high-affinity humanized IgG4 antibody targeting LAG-3 (lymphocyte activation gene-3), which enhances T cell function both in vitro and in vivo, as well as PD-1 blocking activity. LAG-3 is a co-inhibitory receptor associated with impaired T cell function and often co-expressed with PD-1. TSR-033 has anti-tumor activity.

    TSR-033  Chemical Structure
  58. GC68358 Tusamitamab Tusamitamab  Chemical Structure
  59. GC65501 Urelumab Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity, and may enhance cytotoxic activity of Rituximab. Urelumab  Chemical Structure
  60. GC70117 Vibostolimab

    Vibostolimab is a monoclonal antibody that targets anti-TIGIT (T cell immunoglobulin and ITIM domain). Vibostolimab has demonstrated anti-tumor activity and can be used in research for non-small cell lung cancer (NSCLC) and melanoma.

    Vibostolimab  Chemical Structure
  61. GC70123 Vonlerolizumab

    Vonlerolizumab (MOXR 0916) is a humanized IgG agonistic monoclonal antibody specific for OX40. Vonlerolizumab can be used in cancer research.

    Vonlerolizumab  Chemical Structure
  62. GC70124 Vopratelimab

    Vopratelimab (JTX-2011) is a humanized monoclonal antibody that acts as an agonist of the immune globulin G1-kappa and specifically binds to the inducible T cell co-stimulator (ICOS). Vopratelimab retains cross-species reactivity, with an affinity of 0.93 nM for hICOS, 3.7 nM for rat ICOS, and 0.64 nM for mICOS. Vopratelimab has anti-tumor immune response properties.

    Vopratelimab  Chemical Structure
  63. GC65205 Zolbetuximab

    Zolbetuximab (IMAB362) is a monoclonal antibody targeting Claudin-18.2. Zolbetuximab mediates specific killing of Claudin-18.2-positive cells through immune effector mechanisms. Zolbetuximab can be used for the research of gastrointestinal adenocarcinomas and pancreatic tumors.

    Zolbetuximab  Chemical Structure

62 Item(s)

per page

Set Descending Direction